{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:43Z","timestamp":1794003883903,"version":"4.8.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA251072"],"award-info":[{"award-number":["T32CA251072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijgc.2026.104893","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T23:40:01Z","timestamp":1786059601000},"page":"104893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3651-4321","authenticated-orcid":false,"given":"Eliya K.","family":"Shachar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordyn","family":"Silverstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7365-5794","authenticated-orcid":false,"given":"Jeffrey","family":"Gornbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5646-343X","authenticated-orcid":false,"given":"Ritu","family":"Salani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-2933","authenticated-orcid":false,"given":"Beth Y.","family":"Karlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-8688","authenticated-orcid":false,"given":"Dana M.","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2026.104893_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ijgc.2026.104893_bib2","series-title":"NCCN clinical practice guidelines in oncology: [ovarian cancer]. version 2.2026","year":"2026"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104893_bib3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104893_bib4","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.ijgc.2026.104893_bib5","first-page":"2820","article-title":"Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting","volume":"63","author":"Kelley","year":"2003","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104893_bib6","doi-asserted-by":"crossref","first-page":"890","DOI":"10.5858\/arpa.2013-0309-OA","article-title":"Folate receptor \u03b1 associated with triple-negative breast cancer and poor prognosis","volume":"138","author":"Zhang","year":"2014","journal-title":"Arch Pathol Lab Med."},{"issue":"1-2","key":"10.1016\/j.ijgc.2026.104893_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mce.2004.02.020","article-title":"Estrogen and progesterone receptors in ovarian epithelial tumors","volume":"221","author":"Lindgren","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104893_bib8","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1158\/0008-5472.CAN-04-2890","article-title":"Enhancement of folate receptor alpha expression in tumor cells through the glucocorticoid receptor: a promising means to improved tumor detection and targeting","volume":"65","author":"Tran","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijgc.2026.104893_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ygyno.2025.10.029","article-title":"Prognostic implications of HER2 in ovarian cancer: associations with homologous recombination deficiency and folate receptor alpha expression","volume":"203","author":"Park","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104893_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1935","article-title":"756P First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23","volume":"34","author":"Konecny","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104893_bib11","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1158\/1538-7445.AM2025-2945","article-title":"Abstract 2945: PLB-002 is a novel claudin 6 antibody-drug conjugate for ovarian cancer and testicular germ cell cancer","volume":"85","author":"Pan","year":"2025","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104893_bib12","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-22-2981","article-title":"Preclinical efficacy of the antibody-drug conjugate CLDN6-23-ADC for the treatment of CLDN6-positive solid tumors","volume":"29","author":"McDermott","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijgc.2026.104893_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2025.10.034","article-title":"Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma","volume":"204","author":"Furuya","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104893_bib15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104893_bib16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1748-7188-8-23","article-title":"Jaccard index based similarity measure to compare transcription factor binding site models","volume":"8","author":"Vorontsov","year":"2013","journal-title":"Algor Mol Biol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104893_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbrc.2018.09.005","article-title":"ER\u03b1 is a negative regulator of PD-L1 gene transcription in breast cancer","volume":"505","author":"Liu","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijgc.2026.104893_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.582863","article-title":"Estrogen receptor downregulates expression of PD-1\/PD-L1 and infiltration of CD8+ T cells by inhibiting IL-17 signaling transduction in breast cancer","volume":"10","author":"Shuai","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijgc.2026.104893_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1602579","article-title":"Expression patterns of estrogen and androgen receptors in NSCLC patients according to the PD-L1 profile","volume":"16","author":"Rodriguez-Lara","year":"2025","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104893_bib20","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.3390\/ijms24129891","article-title":"Regulation of PD-L1 expression by nuclear receptors","volume":"24","author":"Kiriyama","year":"2023","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.ijgc.2026.104893_bib21","author":"Themeles"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104893_bib22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/PGP.0000000000001176","article-title":"Molecular and clinicopathologic features associated with FOLR1 expression in gynecologic malignancies","volume":"45","author":"Mendoza","year":"2026","journal-title":"Int J Gynecol Pathol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104893_bib23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1541-7786.MCR-20-0835","article-title":"Aberrant Claudin-6-Adhesion signaling promotes endometrial cancer progression via estrogen receptor \u03b1","volume":"19","author":"Kojima","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104893_bib24","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s13046-019-1359-9","article-title":"Estrogen receptor \u03b2 inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy","volume":"38","author":"Song","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104893_bib26","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.2217\/fon-2017-0646","article-title":"Forward I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.ijgc.2026.104893_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105326","article-title":"Past, present, and future perspectives in estrogen-receptor-low breast cancer","volume":"223","author":"Court\u00e8s","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104893_bib28","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104893_bib29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ijgc.2026.104893_bib30","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1007\/s00018-009-0017-3","article-title":"Estrogen and progesterone receptors: from molecular structures to clinical targets","volume":"66","author":"Ellmann","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.ijgc.2026.104893_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1708873","article-title":"Unlocking the mystery of the PD-1\/PD-L1 axis: beyond the checkpoint hype","volume":"16","author":"Desimpel","year":"2025","journal-title":"Front Immunol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2600424X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2600424X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:31:54Z","timestamp":1794000714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2600424X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1048891X2600424X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104893","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actionable biomarker co-expression in advanced ovarian cancer: folate receptor alpha expression and related markers","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104893","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"104893"}}